The MaterniT21® PLUS test:
One test. Multiple answers.

NOT ALL NONINVASIVE PRENATAL TESTS ARE THE SAME

The MaterniT21 PLUS laboratory-developed test is reliably different. It offers more answers pertaining to chromosomal abnormalities (including microdeletions) than any other noninvasive prenatal test using cell-free DNA available today.

This test has the lowest non-reportable rate to date, meaning you have less of a chance of needing a redraw. Results are reported to your doctor, clearly. Positive or negative. Simply, precisely.

Your doctor will get your test results back in approximately 5 days upon receipt of your sample by Sequenom Laboratories.

Choose the MaterniT21 PLUS test for delivering some of the most important information about your unborn baby, early and accurately.

More information early.

Clear, direct results.

Get an answer. The first time.

GET AN ANSWER. THE FIRST TIME.

Testing an unborn baby's DNA from a mother's blood sample is highly complex. There are many different steps and processes that must be correctly completed in order to achieve a result. Some noninvasive prenatal tests by other laboratories fail to deliver an answer in up to 8% of samples run on the first blood draw.[1,2,3,4]

The MaterniT21 PLUS test offers the highest first draw success rate as compared to other tests to date, with fewer than 1% of samples requiring a redraw. This provides your doctor with the peace of mind of a "yes" or "no" answer, avoiding the need for an additional blood draw or a delayed result. Your results are usually available in about 5 days after receipt of your sample in the laboratory.

PERCENTAGE OF SAMPLES WITH NO RESULT (%)[1,2,3,4]



Ask your doctor about the prenatal blood test with more answers for your genetic questions—the MaterniT21 PLUS test.

COMPREHENSIVE CHROMOSOME INFORMATION IN A SINGLE BLOOD TEST

- ☑ **Noninvasive.**
  Uses a blood sample from mother to test fetal DNA. The MaterniT21 PLUS test is not associated with any risk of miscarriage.
- ☑ **Clear, understandable results.**
  The only prenatal test of its kind to offer a positive or negative result (yes or no) for multiple chromosomal abnormalities. Critical information, delivered to your doctor, clearly.
- ☑ **Peace of mind. Time to plan.**
  Knowing more about chromosomal conditions as early as 10 weeks into your pregnancy allows you more time to prepare and enjoy the rest of your pregnancy.

No test is perfect. While results of this testing are highly accurate, false positive and false negative results may occur in rare cases. A negative result does not ensure an unaffected pregnancy. The results of this testing, including the benefits and limitations, should be discussed with your doctor.

Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc., is a CAP-accredited and CLIA-certified molecular diagnostics laboratory dedicated to improving patient outcomes by offering revolutionary laboratory-developed tests for a variety of prenatal and eye conditions. Sequenom Laboratories pioneered NIPT for fetal aneuploidies with the launch of its MaterniT21™ PLUS test, and offers a full menu of prenatal tests.

The MaterniT21® PLUS test is a laboratory-developed test that was developed, validated and is performed exclusively by Sequenom Laboratories in the USA.

SOURCES

1. Palomaki GE, et al. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. *Genet Med*. 2011;13(11):913-920.
2. Palomaki GE, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13, as well as Down syndrome: An international collaborative study. *Genet Med*. 2012;14(3):296-305.
3. Bianchi DW, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. *Obstet Gynecol*. 2012;119(5):890-901.
4. 4. Pergament, et al. Single-Nucleotide Polymorphism-based noninvasive prenatal screening in high-risk and low-risk cohort. *Am J Obstet Gynecol*. 2014;0:1-9. DOI: 10.1097/AOG.0000000000000363.

36-20215R4.55 0515

MaterniT21™ PLUS

A PATIENT'S GUIDE

Choosing the right noninvasive prenatal test

sequenca
126a Remuera Road
Remuera, Auckland 1050
New Zealand
09 524 7664
info@sequenca.nz
www.sequenca.nz

sequenom Laboratories — QUALITY OF SCIENCE™

MaterniT21™ PLUS

A SPECIAL TEST FOR A SPECIAL LIFE OCCURRENCE

Being pregnant is a special life-changing occurrence—it may only happen once or twice in your lifetime. Upon finding out you are pregnant, many different tests will be offered to you by your doctor as part of your prenatal care. Standard prenatal testing offers glimpses into the pregnancy, but comes with some risk of miscarriage. Now, using technology only recently available, your doctor can provide additional testing options.

THE MATERNIT21 PLUS TEST

The MaterniT21™ PLUS noninvasive laboratory-developed test is indicated for use in women at increased risk for fetal chromosomal abnormalities.

Using state-of-the-art DNA analysis, the test provides highly accurate, easy-to-understand "yes or no" results about the relative amount of fetal (unborn baby's) chromosomal material associated with conditions such as Trisomy 21 (Down syndrome).

KNOWLEDGE IS EMPOWERING

Choosing the MaterniT21 PLUS test to find out more about your pregnancy is a decision that does not have to be difficult—you are selecting the most comprehensive prenatal blood test available. It requires only a blood sample from you, drawn as early as 10 weeks of pregnancy.

CHROMOSOMAL ABNORMALITIES AND MICRODELETIONS

Down syndrome, also known as trisomy 21, is a genetic disorder caused by the presence of a third copy of chromosome 21. Down syndrome is the most common chromosome abnormality in humans.

Other rare genetic disorders include "microdeletion syndromes", caused by a chromosomal deletion, or missing material from a particular chromosome.

Currently, to diagnose prenatal microdeletions a procedure such as amniocentesis or chorionic villus sampling (CVS) is required. However, these are invasive procedures that are known to carry a small risk of miscarriage.

THE "DIAGNOSTIC ODYSSEY"

Since amniocentesis and CVS are not common practice for all pregnancies, it may be years before a child born with a microdeletion syndrome is properly identified or diagnosed with a specialty test. During this period, families may have to take their child to multiple specialists to seek a diagnosis. This is sometimes referred to as the "diagnostic odyssey."

The MaterniT21 PLUS test is able to detect these microdeletions as early as 10 weeks into your pregnancy.

THE MATERNIT21 PLUS TEST

The MaterniT21 PLUS test analyzes more chromosomal regions than any other noninvasive prenatal test, to date.



OTHER TESTS

Other noninvasive prenatal tests currently provide analysis on fewer chromosomal regions.



MICRODELETION TESTING

The MaterniT21 PLUS test is the first prenatal test to date to introduce microdeletion testing to help detect microdeletion syndromes from as early as 10 weeks into your pregnancy. These conditions are associated with profound consequences in the life and health of your child. This information can help your doctor recommend specialized and personalized care for you and your baby, before and after delivery. The MaterniT21 PLUS test currently offers information associated with the following syndromes, with more in development:

Trisomy 21 (Down syndrome)
Trisomy 18 (Edwards syndrome)
Trisomy 13 (Patau syndrome)
Trisomy 16*
Trisomy 22*
45,X (Turner syndrome)*
47,XXY (Klinefelter syndrome)*
47,XXX (Triple X syndrome)*
47,XYY (XYY syndrome)*
22q (DiGeorge syndrome)*
5p (Cri-du-chat syndrome)*
1p36 deletion syndrome*
15q (Angelman syndrome)*
15q (Prader-Willi syndrome)*
11q (Jacobsen syndrome)*
8q (Langer-Giedion syndrome)*
4p (Wolf-Hirschhorn syndrome)*

* Reported as an Additional Finding

PREGNANT WITH MULTIPLE BABIES?

Some other noninvasive prenatal tests available have difficulty distinguishing fetal chromosomal abnormalities when there is more than one baby in the womb. The MaterniT21 PLUS test is able to accurately detect chromosomal abnormalities in multiple birth pregnancies; however, it won't be able to tell you which baby is affected.

With over 300,000 samples tested, and reporting on over 6,000 multiple gestations, the MaterniT21 PLUS test is well-suited for use by doctors in *in vitro* fertilization clinics and assisted conception units.